In a major breakthrough in the deadly cough syrup scandal, police have arrested G. Ranganathan, owner of Sresan Pharmaceuticals, over the production of Coldrif syrup allegedly laced with toxic chemicals. The incident has implicated the company in multiple child deaths in Madhya Pradesh.
Glimpse:
Authorities in India have detained G. Ranganathan, owner and director of Sresan Pharma, in connection with the Coldrif cough syrup linked to the deaths of at least 17 children under the age of five. The arrest took place in Chennai, and procedures are underway for his transfer to Madhya Pradesh for further legal proceedings. During the operation, investigators seized critical documents, drug samples, and manufacturing records from the company’s facility in Tamil Nadu, revealing serious lapses in compliance and safety protocols. The incident has ignited national outrage around drug regulation, manufacturing oversight, and accountability.
The long pending investigation into the toxic cough syrup tragedy has reached a dramatic milestone. G. Ranganathan, the proprietor behind Sresan Pharmaceuticals, has been apprehended in Chennai as the prime accused in the Coldrif syrup scandal that has already claimed numerous young lives.
Reports confirm the arrest was carried out by a Special Investigation Team (SIT) dispatched from Madhya Pradesh. Ranganathan, aged around 75, was taken into custody from his residence in the Kodambakkam area and produced for questioning. Authorities are processing a transit remand to bring him to Chhindwara (MP), where the bulk of the deaths occurred.
During the arrest operation, officials secured documents, production records, and samples from the company’s manufacturing unit in Kancheepuram. Early indications suggest widespread noncompliance: failure to use pharma-grade raw materials, missing compliance with good manufacturing practices, and absence of proper safety protocols. Authorities also found multiple regulatory violations in the production records submitted by Sresan Pharma.
Ranganathan now faces serious charges including drug adulteration, culpable homicide (not amounting to murder), and violating the Drugs & Cosmetics laws. The move underscores the government’s resolve to hold responsible parties accountable, especially given the intense public outrage.
But the case is still far from over. Investigators will expand their probe into the supply chain, including chemical suppliers, distributors, and oversight gaps in local regulatory bodies. As this legal journey unfolds, there will be pressures to tighten pharmaceutical oversight nationwide to restore public trust.
“Today’s arrest sends a strong message: those responsible for undermining drug safety will not escape accountability,”
By
HB Team
